Reported Q: Q4 2024 Rev YoY: -3.0% EPS YoY: -64.7% Move: -3.52%
Teladoc Health Inc
4LL.F
€4.00 -3.52%
Exchange FSX Sector Healthcare Industry Medical Healthcare Information Services
Q4 2024
Published: Feb 27, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for 4LL.F

Reported

Report Date

Feb 27, 2025

Quarter Q4 2024

Revenue

640.49M

YoY: -3.0%

EPS

-0.28

YoY: -64.7%

Market Move

-3.52%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $640.49M down 3% year-over-year
  • EPS of $-0.28 decreased by 64.7% from previous year
  • Gross margin of 70.5%
  • Net income of -48.41M
  • "" -
4LL.F
Company 4LL.F

Executive Summary

Teladoc Health’s Q4 2024 results reflect a transition to improved operating discipline amid a still-challenging profitability backdrop. Revenue for the quarter was $640.5 million, essentially flat year over year and broadly in line with the prior quarter at $640.5 million, signaling stabilization in top-line trends after a period of growth headwinds. Gross margin remained robust at 70.5%, delivering $451.6 million in gross profit, yet the company delivered an operating loss of $48.2 million and a net loss of $48.4 million, underscoring ongoing cost allocation pressures and investments that have yet to fully translate into normalized profitability.

From a cash-flow perspective, Teladoc generated $85.9 million of operating cash flow and $56.3 million of free cash flow in Q4, supported by a healthy cash balance of $1.30 billion and a net debt position of roughly $286 million. This liquidity framework provides near-term flexibility to fund strategic initiatives, including platform expansion and international growth opportunities, while absorbing continued investments in SG&A and product development. The balance sheet remains solid with total assets of $3.52 billion and current liquidity metrics (current ratio 1.77, quick ratio 1.73, cash ratio 1.38) signaling adequate short-term oversight of working capital needs.

On a comparative basis, Teladoc’s gross margin sits at the higher end of the peer set, but the company remains the only material loss-maker among the selected peers in this snapshot, with a negative net income and negative earnings per share for Q4. The market continues to price Teladoc with a higher weight on cash-generation capability and long-term growth, given secular tailwinds in telehealth and virtual care adoption, but execution of cost containment and revenue expansion remains critical to achieving sustained profitability. Investors should monitor trajectory of revenue growth in IIntegrated Care and BetterHelp, ongoing leverage in operating expenses, and the pace of cash-flow conversion as catalysts for a more favorable earnings trajectory.

Key Performance Indicators

Revenue
Decreasing
640.49M
QoQ: 0.00% | YoY: -3.03%
Gross Profit
Decreasing
451.56M
70.50% margin
QoQ: -2.00% | YoY: -3.33%
Operating Income
Increasing
-48.22M
QoQ: -8.59% | YoY: 44.67%
Net Income
Decreasing
-48.41M
QoQ: -45.48% | YoY: -67.56%
EPS
Decreasing
-0.28
QoQ: -40.00% | YoY: -64.71%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 626.44 -0.28 -2.2% View
Q2 2025 631.90 -0.19 -1.6% View
Q1 2025 629.37 -0.53 -2.6% View
Q4 2024 640.49 -0.28 -3.0% View
Q3 2024 640.51 -0.19 -3.0% View